HC Wainwright Forecasts Weaker Earnings for Journey Medical

Journey Medical Corporation (NASDAQ:DERM) – Research analysts at HC Wainwright cut their FY2026 earnings estimates for Journey Medical in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.18 per share for the year, down from their prior estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical’s FY2027 earnings at $1.17 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $1.95 EPS.

Several other research firms have also recently commented on DERM. Lake Street Capital boosted their price target on shares of Journey Medical from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of Journey Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Journey Medical has a consensus rating of “Hold” and a consensus target price of $12.17.

Journey Medical Stock Down 1.8%

DERM stock traded down $0.14 during mid-day trading on Friday, reaching $7.56. The company had a trading volume of 97,347 shares, compared to its average volume of 124,870. The firm has a fifty day simple moving average of $7.63 and a 200 day simple moving average of $7.32. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.95 and a current ratio of 1.27. Journey Medical has a fifty-two week low of $3.54 and a fifty-two week high of $9.40. The company has a market capitalization of $198.77 million, a price-to-earnings ratio of -21.59 and a beta of 0.80.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Journey Medical had a negative net margin of 14.58% and a negative return on equity of 42.71%. The business had revenue of $17.63 million during the quarter, compared to analysts’ expectations of $18.85 million.

Hedge Funds Weigh In On Journey Medical

Several institutional investors have recently added to or reduced their stakes in DERM. Pale Fire Capital SE purchased a new stake in shares of Journey Medical during the first quarter worth approximately $161,000. Focus Partners Advisor Solutions LLC purchased a new position in Journey Medical during the 2nd quarter worth $72,000. Titleist Asset Management LLC lifted its stake in shares of Journey Medical by 18.3% in the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company’s stock worth $76,000 after acquiring an additional 2,000 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of Journey Medical by 55.1% in the third quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company’s stock valued at $2,521,000 after acquiring an additional 125,818 shares in the last quarter. Finally, SJS Investment Consulting Inc. acquired a new position in shares of Journey Medical during the third quarter worth about $107,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.